参考文献/References:
[1] 郭晓波,蔺 京,白涛涛,等.骨髓增殖性肿瘤患者外周血单个核细胞JAK2 V617F基因突变检测分析[J].现代检验医学杂志,2014,29(4):112-113,115.
Guo XB,Lin J,Bai TT,et al.Analysis of JAK2 V-617F gene mutationin peripheral blood mononuclear cells of patients with myeloproliferative neoplasms[J].J Mod Lab Med,2014,29(4):112-113,115.
[2] 董 莹,朱华锋,侯莉萍,等.骨髓增殖性肿瘤120例JAK2-V617F基因突变的临床分析[J].白血病.淋巴瘤,2015,24(7):433-436.
Dong Y,Zhu HF,Hou LP,et al.Clinical analysis of JAK2 V617F genemutation in 120 patients with myeloproliferative neoplasms[J].Journal of Leukemia & L-ymphoma,2015,24(7):433-436.
[3] Arber DA,Orazi A,Hasserjian R,et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J].Blood,2016,127(20):2391-2405.
[4] 郭慧梅,贺建辉,李云鹏,等.骨髓增殖性肿瘤患者JAK2-V617F突变和脑血管事件的相关性研究[J].医学研究与教育杂志,2014,31(6):28-30.
Guo HM,He JH,Li YP,et al.Study on the correlation of JAK2-V617Fmutation and cerebrovascular events in patients with myeloproliferative neoplasms[J].Journal of Medical Research and Education,2014,31(6):28-30.
[5] 白雪燕,白贝贝,于小蕊,等.骨髓增殖性肿瘤伴发卒中的临床分析[J].中国卒中杂志,2013,8(1):31-38.
Bai XY,Bai BB,Yu XR,et al.Clinical analysis of myeloproliferative neoplasms with stroke[J].Chinese Journal of Stroke,2013,8(1):31-38.
[6] Rumi E,Pietra D,Ferretti V,et al.JAK2 or CALR mutation status definessubtypes of essential thrombocythemia with substantilly different clinical course and outcomes[J].Blood,2014,123(10):1544-1551.